CMS is delaying the effective date of a rule to let drug manufacturers report multiple best prices on their products if states opt to participate in value-based purchasing models.
CMS Delays Implementing Rule Allowing Multiple Best Prices for Drugs Until Next July
The Biden administration said yesterday it is delaying by six months the effective date of a Trump administration final rule to let drug manufacturers report multiple best prices on their products if states opt to participate in value-based purchasing (VBP) models.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.